Leerink Partners Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $153
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $140
BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $160
Vaxcyte's V AX-31 Demonstrates Market Disruption Potential With Strong Clinical Trial Results; Buy Rating Reaffirmed With Increased Price Target
Buy Rating Affirmed for Vaxcyte Ahead of Key VAX-31 Phase 1/2 Milestone
Vaxcyte Analyst Ratings
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating
Optimistic Buy Rating for Vaxcyte Amidst Promising Vaccine Candidate Progress and Strategic Positioning
Jefferies Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $108
Strong Buy Rating for Vaxcyte as VAX-31 Poised to Capture Significant PCV Market Share
Jefferies Keeps Their Buy Rating on Vaxcyte (PCVX)
TD Cowen Remains a Buy on Vaxcyte (PCVX)
Vaxcyte Analyst Ratings
Vaxcyte Analyst Ratings
Analysts Conflicted on These Healthcare Names: Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals Inc (AMLX) and Vaxcyte (PCVX)
Analysts Offer Insights on Healthcare Companies: Herbalife (HLF), Alignment Healthcare (ALHC) and Vaxcyte (PCVX)
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Apogee Therapeutics, Inc. (APGE)
Buy Rating Reaffirmed for Vaxcyte Amid Financial Discipline and Promising Vaccine Trials
Buy Rating Affirmed for Vaxcyte Amid Promising Pipeline and Clear Milestones
Vaxcyte Analyst Ratings